Click Therapeutics Acquires Defunct Better Therapeutics’ Assets

Click Therapeutics has acquired the assets of Better Therapeutics in a move to accelerate development initiatives in obesity and cardiometabolic disease.
 
(Formerly) San Francisco-based Better Therapeutics closed its doors and terminated all of itsemployees on March 13, 2024.
 
The specific assets acquired include AspyreRx (BT-001), the first U.S. Food and Drug Administration (FDA)-authorized prescription digital therapeutic for type 2 diabetes, and BT-004, which was recently granted FDA Breakthrough Device Designation to treat metabolic dysfunction-associated steatohepatitis (MASH).
 
Other assets are BT-002, for reduction of blood pressure in hypertensive patients, and BT-003, to reduce LDL cholesterol in patients with hyperlipidemia.
 
Click’s move into obesity and cardiometabolic disease is the culmination of progress over recent years. This includes initiating CT-181, a prescription digital therapeutic candidate for obesity. The company has done research and identified features like smart titration and personalized side-effect management to meaningfully enhance anti-obesity and cardiometabolic medication outcomes and value.
 
Integrating Better Therapeutics’ intellectual property with Click’s development plans for obesity is anticipated to both accelerate development timelines and yield a powerful digital therapy for chronic weight management. The resulting digital therapeutic will be to treat obesity in combination with anti-obesity and diabetes medications like GLP-1s, including current injectables and future oral formulations.
 
It will leverage both AspyreRx’s clinically-validated digital behavioral therapy, developed over the course of nine years, and Click’s artificial intelligence (AI)-enabled platform, which combines advanced engagement techniques with proprietary digital mechanisms of action to treat disease. Integrating Better’s assets with Click’s platform Similar will enabled similar development opportunities in type 2 diabetes, hypertension, hyperlipidemia, and MASH.
 
Digital therapeutics can offer individual neuro-behavioral treatment, responsive to each patient, that delivers the comprehensive approach needed to support long-term outcomes. By delivering this treatment alongside medication, drug-software combination treatments seek to boost clinical outcomes, enhance patient experience, and extend persistence on treatment compared to pharmacotherapy alone.
 
Further, data derived from real-world use of these smart medications can inform appropriate patient selection, support value-based contracting, and maximize value for stakeholders.
 
“There is immense potential in the cardiometabolic space for next-generation ‘smart’ therapeutics that enhance patient care and provider capabilities,” said Rich DeNunzio, chief commercial officer of Click Therapeutics. “The current one-size-fits-all approach to obesity management can be improved with innovative digital therapeutics that tailor treatments to individual needs, leading to improved patient outcomes and the opportunity to create data-driven contracting models with payers. By collaborating with pharma, payers, providers and patients to layer these capabilities onto the latest drugs, we can transform obesity care and enable our partners to succeed in what is soon to be a highly competitive market.”